郑州大学学报（医学版）
鄭州大學學報（醫學版）
정주대학학보（의학판）
JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES)
2015年
4期
550-555
,共6页
杜习智%赵成龙%秦玉花%赵红卫
杜習智%趙成龍%秦玉花%趙紅衛
두습지%조성룡%진옥화%조홍위
奥沙利铂%卡铂%非小细胞肺癌%meta 分析
奧沙利鉑%卡鉑%非小細胞肺癌%meta 分析
오사리박%잡박%비소세포폐암%meta 분석
oxaliplatin%carboplatin%NSCLC%meta-analysis
目的：：系统评价奥沙利铂联合化疗与卡铂联合化疗治疗中晚期非小细胞肺癌(NSCLC)的有效性和安全性。方法：检索 Medline、Cochrane Library、PubMed、EMbase、CNKI、CBM、VIP 和 WANFANG 数据库,收集关于奥沙利铂联合化疗与卡铂联合化疗治疗中晚期 NSCLC 的随机对照试验(RCT),采用 RevMan 5.1进行 meta 分析。结果：最终纳入6个 RCT,共784例患者。 Meta 分析显示,两个方案的客观缓解率(OR =0.82,95% CI：0.60~1.14)、客观控制率(OR =0.97,95% CI：0.72~1.31)、Ⅲ-Ⅳ度恶心、呕吐发生率(OR =1.02,95% CI：0.55~1.91)差异无统计学意义,而奥沙利铂联合方案Ⅲ-Ⅳ度贫血(OR =0.18,95% CI：0.05~0.63)、Ⅲ-Ⅳ度白细胞减少(OR =0.29,95%CI：0.15~0.57)、Ⅲ-Ⅳ度中性粒细胞减少(OR =0.41,95% CI：0.28~0.61)、Ⅲ-Ⅳ度血小板减少(OR =0.20,95%CI：0.05~0.71)的发生率较卡铂联合方案明显降低,神经毒性的发生率明显升高(OR =30.58,95% CI：7.17~130.38)。结论：奥沙利铂联合化疗方案治疗中晚期 NSCLC 疗效与卡铂联合化疗方案相似,但安全性更好。
目的：：繫統評價奧沙利鉑聯閤化療與卡鉑聯閤化療治療中晚期非小細胞肺癌(NSCLC)的有效性和安全性。方法：檢索 Medline、Cochrane Library、PubMed、EMbase、CNKI、CBM、VIP 和 WANFANG 數據庫,收集關于奧沙利鉑聯閤化療與卡鉑聯閤化療治療中晚期 NSCLC 的隨機對照試驗(RCT),採用 RevMan 5.1進行 meta 分析。結果：最終納入6箇 RCT,共784例患者。 Meta 分析顯示,兩箇方案的客觀緩解率(OR =0.82,95% CI：0.60~1.14)、客觀控製率(OR =0.97,95% CI：0.72~1.31)、Ⅲ-Ⅳ度噁心、嘔吐髮生率(OR =1.02,95% CI：0.55~1.91)差異無統計學意義,而奧沙利鉑聯閤方案Ⅲ-Ⅳ度貧血(OR =0.18,95% CI：0.05~0.63)、Ⅲ-Ⅳ度白細胞減少(OR =0.29,95%CI：0.15~0.57)、Ⅲ-Ⅳ度中性粒細胞減少(OR =0.41,95% CI：0.28~0.61)、Ⅲ-Ⅳ度血小闆減少(OR =0.20,95%CI：0.05~0.71)的髮生率較卡鉑聯閤方案明顯降低,神經毒性的髮生率明顯升高(OR =30.58,95% CI：7.17~130.38)。結論：奧沙利鉑聯閤化療方案治療中晚期 NSCLC 療效與卡鉑聯閤化療方案相似,但安全性更好。
목적：：계통평개오사리박연합화료여잡박연합화료치료중만기비소세포폐암(NSCLC)적유효성화안전성。방법：검색 Medline、Cochrane Library、PubMed、EMbase、CNKI、CBM、VIP 화 WANFANG 수거고,수집관우오사리박연합화료여잡박연합화료치료중만기 NSCLC 적수궤대조시험(RCT),채용 RevMan 5.1진행 meta 분석。결과：최종납입6개 RCT,공784례환자。 Meta 분석현시,량개방안적객관완해솔(OR =0.82,95% CI：0.60~1.14)、객관공제솔(OR =0.97,95% CI：0.72~1.31)、Ⅲ-Ⅳ도악심、구토발생솔(OR =1.02,95% CI：0.55~1.91)차이무통계학의의,이오사리박연합방안Ⅲ-Ⅳ도빈혈(OR =0.18,95% CI：0.05~0.63)、Ⅲ-Ⅳ도백세포감소(OR =0.29,95%CI：0.15~0.57)、Ⅲ-Ⅳ도중성립세포감소(OR =0.41,95% CI：0.28~0.61)、Ⅲ-Ⅳ도혈소판감소(OR =0.20,95%CI：0.05~0.71)적발생솔교잡박연합방안명현강저,신경독성적발생솔명현승고(OR =30.58,95% CI：7.17~130.38)。결론：오사리박연합화료방안치료중만기 NSCLC 료효여잡박연합화료방안상사,단안전성경호。
Aim: To determine the efficacy and toxicity of oxaliplatin based chemotherapy versus carboplatin based chemotherapy for advanced non-small cell lung cancer(NSCLC). Methods: The randomized controlled trials(RCTs) on oxaliplatin based chemotherapy versus carboplatin based chemotherapy for advanced NSCLC were searched in Medline, the Cochrane Library, PubMed, EMbase, CNKI, CBM, VIP and WANFANG Data base. A meta-analysis was carried out by RevMan 5. 1. Results: Six trials that included a total of 784 patients were analyzed. The meta-analysis demonstrated that, compared with the carboplatin based chemotherapy, oxaliplatin based chemotherapy could decrease the risks of hematologi-cal toxicity, including grade 3 - 4 anemia(OR = 0. 18, 95% CI:0. 05 - 0. 63), grade 3 - 4 leukopenia(OR = 0. 29, 95%CI:0. 15 - 0. 57), grade 3 - 4 neutropenia (OR = 0. 41, 95% CI:0. 28 - 0. 61), and grade 3 - 4 thrombocytopenia(OR =0. 20, 95% CI:0. 05 - 0. 71), but increase the risk of neurotoxicity(OR = 30. 58, 95% CI:7. 17 - 130. 38). There were no significant differences between the two groups in overall response rate(OR = 0. 82, 95% CI:0. 60 - 1. 14), disease con-trol rate(OR = 0. 97, 95% CI:0. 72 - 1. 31), or grade 3-4 nausea and vomiting(OR = 1. 02, 95% CI:0. 55 - 1. 91). Con-clusion: Oxaliplatin based chemotherapy has similar efficacy to carboplatin based chemotherapy, but milder toxicity.
